Pin your most used calculators here by clicking the star in the dropdown.
IPSS-R for MDS
%
g/dL
x10⁹/L
x10⁹/L
Clinical Context & Background
The IPSS-R defines risk groups for survival and risk of AML evolution in untreated MDS patients. It includes cytogenetics, bone marrow blasts, hemoglobin, platelets, and ANC. Note: The molecular IPSS-M (2022) provides further refinement if NGS data is available.
Formula Logic
Sum of weighted points from 5 variables.Reference Data
| Risk Group | Total Score | Median Survival |
|---|---|---|
| Very Low | ≤ 1.5 | 8.8 years |
| Low | > 1.5 - 3 | 5.3 years |
| Intermediate | > 3 - 4.5 | 3.0 years |
| High | > 4.5 - 6 | 1.6 years |
| Very High | > 6 | 0.8 years |
Evidence-based oncology decision support. Verify with clinical guidelines.